Ticagrelor Monotherapy After One Month Algorithm Tool
Clinical assessment
Complete the patient factors below. This decision aid supports, but does not replace, individualized clinical judgment.
Clinical context
Dual antiplatelet therapy (DAPT) with aspirin and an oral P2Y12 inhibitor remains the default strategy for at least 12 months after ACS in patients who are not at high bleeding risk. The 2025 ACC/AHA ACS guideline recommends transition to ticagrelor monotherapy at or beyond one month after PCI for patients who have tolerated ticagrelor-based DAPT, as a bleeding-reduction strategy.
How to use this pathway
- Confirm the index presentation, PCI date, current drugs, adherence, contraindications, and clinical stability.
- Use a validated bleeding-risk framework and review ischemic and procedural risk rather than relying on a single yes/no item.
- Patients requiring long-term oral anticoagulation need a separate antithrombotic strategy; the ACS guideline generally favors a P2Y12 inhibitor, preferably clopidogrel, after early aspirin discontinuation.
- This simplified tool does not calculate a validated risk score and cannot replace review of the full guideline, angiographic findings, or specialist judgment.
References
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. J Am Coll Cardiol. 2025.
doi:10.1016/j.jacc.2024.11.009Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after PCI in patients with ACS (ULTIMATE-DAPT). Lancet. 2024;403:1866–1878.
doi:10.1016/S0140-6736(24)00473-2 · PMID: 38599220Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With ACS: The TICO Randomized Clinical Trial. JAMA. 2020;323:2407–2416.
doi:10.1001/jama.2020.7580Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.